Profil
Augusto Ocana was a Director at CytoCore, Inc. He was also a Director, General Manager & Senior Vice President at C.H.
Werfen, Inc. from 1999 to 2006.
From 2006 to 2018, he was a Director at MEDITE Cancer Diagnostics, Inc.
Ehemalige bekannte Positionen von Augusto Ocana
| Unternehmen | Position | Ende |
|---|---|---|
| MEDITE CANCER DIAGNOSTICS INC | Direktor/Vorstandsmitglied | 23.01.2018 |
| C.H. Werfen, Inc. | Direktor/Vorstandsmitglied | 01.01.2006 |
CytoCore, Inc.
 CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MEDITE CANCER DIAGNOSTICS INC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
CytoCore, Inc.
CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Health Technology |
| C.H. Werfen, Inc. |
